banner ad
banner ad

Data on Xeomin® (incobotulinumtoxinA) in the Treatment of Blepharospasm to be Presented at the 115th Annual Meeting of the American Academy of Ophthalmology

October 25, 2011 |

Merz Pharmaceuticals, LLC, today announced that data from studies evaluating the dosing and adverse event profiles of Xeomin® (incobotulinumtoxinA), a botulinum toxin type A free from accessory proteins, in the treatment of blepharospasm (eyelid spasms) will be presented at the 115th Annual Meeting of the American Association of Ophthalmology (AAO) in Orlando, Fla.These data include an extension of the Phase III, randomized, placebo-controlled, double-blind trial that assessed the safety and efficacy of XEOMIN in blepharospasm, which was recently published in the July 2011 issue of Movement Disorders, the official journal of the Movement Disorders Society. Findings from the Phase III trial demonstrate that XEOMIN was significantly more efficacious than placebo, as observed in the primary efficacy variable (change in Jankovic Rating Scale severity subscore six weeks following treatment), when administered in a single treatment session to patients with blepharospasm who were previously treated with onabotulinumtoxinA (Botox®).

Blepharospasm, also referred to as benign essential blepharospasm, is a rare condition that possibly goes undiagnosed or misdiagnosed.

Read the full Press Release at http://www.prnewswire.com/news-releases/data-on-xeomin-incobotulinumtoxina-in-the-treatment-of-blepharospasm-to-be-presented-at-the-115th-annual-meeting-of-the-american-academy-of-ophthalmology-132519343.html

About the Author (Author Profile)

Comments are closed.

banner ad
banner ad